Malaria vaccine R&D in the Decade of Vaccines: Breakthroughs, challenges and opportunities

Vaccine

Volumn 31, Issue SUPPL2, 2013, Pages

  Birkett, Ashley J ^a   Moorthy, Vasee S ^b   Loucq, Christian ^c   Chitnis, Chetan E ^d   Kaslow, David C ^a  

^a PATH Malaria Vaccine Initiative   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c International Vaccine Institute   (South Korea)

^d INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Elimination; Eradication; Malaria; Malaria Vaccine Technology Roadmap; MalERA; P. falciparum; P. vivax; Vaccine

Indexed keywords

MALARIA VACCINE;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE TRANSMISSION; HUMAN; HUMORAL IMMUNITY; MALARIA; MALARIA CONTROL; MOSQUITO; NONHUMAN; PASSIVE IMMUNIZATION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VACCINATION;

AFRICA; BIOMEDICAL RESEARCH; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; T-LYMPHOCYTES;

EID: 84876700755     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.040     Document Type: Review

References (72)

1. WHO. World Malaria Report 2011, . http://www.who.int/malaria/world_malaria_report_2011/en/.
2. malERA. A Research Agenda for Malaria Eradication, ; 2011. http://www.ploscollections.org/malera2011.
3. Malaria Vaccine Technology Roadmap, ; 2006. http://www.malariavaccineroadmap.net/pdfs/Malaria_Vaccine_TRM_Final.pdf.
4. Roberts L., Enserink M. Malaria. Did they really say...eradication?. Science 2007, 318(5856):1544-1545.
5. Alonso P.L., et al. A research agenda to underpin malaria eradication. PLoS Med 2011, 8(1):e1000406.
6. A research agenda for malaria eradication: vaccines. PLoS Med 2011, 8(1):e1000398. The malERA Consultative Group on Vaccines.
7. Malaria Vaccine Technology Roadmap: update of vision and strategic goal underway, ; 2012. http://www.who.int/vaccine_research/diseases/malaria/roadmap_update_jul12/en/index.html.
8. Brooks A., et al. Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design. Glob Public Health 2012, 7(9):931-945.
9. W.F.M.V.R.T. http://www.who.int/vaccine_research/links/Rainbow/en/index.html.
10. Schwartz L., et al. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 2012, 11(11).
11. Schwartz L., et al. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 2012, 11:p11.
12. Cohen J., et al. The malaria vaccine candidate RTS,S/AS is in phase III clinical trials. Ann Pharm Fr 2010, 68(6):370-379.
13. Leach A., et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J 2011, 10:224.
14. Vekemans J., Leach A., Cohen J. Development of the RTS,S/AS malaria candidate vaccine. Vaccine 2009, 27(Suppl. 6):G67-G71.
15. Moorthy V., Reed Z., Smith P.G. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine 2007, 25(28):5115-5123.
16. Moorthy V.S., Reed Z., Smith P.G. MALVAC 2008: measures of efficacy of malaria vaccines in phase 2b and phase 3 trials - scientific, regulatory and public health perspectives. Vaccine 2009, 27(5):624-628.
17. Lievens M., et al. Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS,S/AS01 malaria vaccine in African children. Malar J 2011, 10:222.
18. Agnandji S.T., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365(20):1863-1875.
19. The RTS, S.C.T.P. A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. N Engl J Med 2012, 594.
20. Asante K.P., et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 2011, 11(10):741-749.
21. Agnandji S.T., et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis 2011, 202(7):1076-1087.
22. Garcon N., Chomez P., Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6(5):723-739.
23. Global Vaccine Safety Blueprint Project, ; 2012. http://www.who.int/immunization_safety/activities/GVS_blueprint_project/en/index.html.
24. Roestenberg M., et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009, 361(5):468-477.
25. Kester K.E., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200(3):337-346.
26. Epstein J.E., et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 2007, 196(1):145-154.
27. Sauerwein R.W., Roestenberg M., Moorthy V.S. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011, 11(1):57-64.
28. Hoffman S.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002, 185(8):1155-1164.
29. Clyde D.F. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. Bull World Health Organ 1990, 68(Suppl.):9-12.
30. Epstein J.E., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 2011, 334(6055):475-480.
31. Stoute J.A., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997, 336(2):86-91.
32. Roestenberg M., et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011, 377(9779):1770-1776.
33. Dunachie S.J., et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS S/AS02A and MVA-CS. Vaccine 2006, 24(15):2850-2859.
34. Laurens M.B., et al. A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. Vaccine 2012, 30(36):5302-5304.
35. Roestenberg M., et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2013, 88(1):5-13.
36. Herrera S. Case report: successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors. Am J Trop Med Hyg 2009, 81(5):740-746.
37. Herrera S., et al. Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am J Trop Med Hyg 2011, 84(2 Suppl.):4-11.
38. Bennett J.W., Ockenhouse CF Y.A. Phase 1/2a open-label dose safety, reactogenicity, immunogenicity and efficacy of the candidate Plasmodium vivax malaria protein 001 (VMP001) administered intramuscularly with GSK Biologicals' Adjuvant System AS01B in healthy malaria-naïve adults. ASTMH Annual Meeting (Abstract #953) 2011.
39. Romero P., et al. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989, 341(6240):323-326.
40. Stewart V.A., et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun 2007, 75(5):2283-2290.
41. Miyahira Y., et al. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc Natl Acad Sci U S A 1998, 95(7):3954-3959.
42. Workshop on Heterologous Prime-Boost Strategies for HIV, Malaria and Tuberculosis Vaccines, ; 2012: Washington DC, USA. http://www.who.int/vaccine_research/diseases/malaria/niaid_workshop_hiv_malaria_tb_2012/en/index.htmlNIAID/WHO.
43. Cech P.G., et al. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. PLoS ONE 2011, 6(7):e22273.
44. Gardner M.J., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002, 419(6906):498-511.
45. Carlton J.M., et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 2008, 455(7214):757-763.
46. Mlambo G., Kumar N. Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines. Eukaryot Cell 2008, 7(11):1875-1879.
47. Doolan D.L., et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A 2003, 100(17):9952-9957.
48. Pinder M., et al. MALVAC 2009: progress and challenges in development of whole organism malaria vaccines for endemic countries, 3-4 June 2009, Dakar, Senegal. Vaccine 2009, 28(30):4695-4702.
49. Sattabongkot J., et al. Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. Am J Trop Med Hyg 2006, 74(5):708-715.
50. Bouharoun-Tayoun H., et al. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995, 182(2):409-418.
51. Persson C., et al. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J Immunol 2002, 169(12):6681-6685.
52. Thompson J., et al. What can transgenic parasites tell us about the development of Plasmodium-specific immune responses?. Parasite Immunol 2008, 30(4):223-233.
53. HIV Vaccine Trials Network (HVTN) Laboratory, . http://labs.fhcrc.org/mcelrath/HVTN_Lab_page/index.html.
54. Thera M.A., et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med 2011, 365(11):1004-1013.
55. Bang G., et al. Pre-clinical assessment of novel multivalent MSP3 malaria vaccine constructs. PLoS ONE 2011, 6(12):pe28165.
56. Genton B., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002, 185(6):820-827.
57. Moorthy V.S., et al. Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. Vaccine 2009, 27(42):5719-5725.
58. Tham W.H., Healer J., Cowman A.F. Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum. Trends Parasitol 2012, 28(1):23-30.
59. Douglas A.D., et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2011, 2. Article number 601.
60. Duncan C.J., Hill A.V., Ellis R.D. Can growth inhibition assays (GIA) predict blood-stage 701 malaria vaccine efficacy?. Hum Vaccin Immunother 2012, 8(6).
61. Salanti A., et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 2004, 200(9):1197-1203.
62. Trimnell A.R., et al. Global genetic diversity and evolution of var genes associated with placental and severe childhood malaria. Mol Biochem Parasitol 2006, 148(2):169-180.
63. Ditlev S.B., et al. Identification and characterization of B-cell epitopes in the DBL4epsilon domain of VAR2CSA. PLoS ONE 2012, 7(9):e43663.
64. Gething P.W., et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012, 6(9):pe1814.
65. Gething P.W., et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 2011, 10:p378.
66. Ceesay S.J., et al. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet 2008, 372(9649):1545-1554.
67. O'Meara W.P., et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 2008, 372(9649):1555-1562.
68. Smith D.L., et al. Revisiting the basic reproductive number for malaria and its implications for malaria control. PLoS Biol 2007, 5(3):pe42.
69. Wu Y., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 2008, 3(7):e2636.
70. Malkin E.M., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005, 23(24):3131-3138.
71. Ockenhouse C.F., et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998, 177(6):1664-1673.
72. Penny M., Maire N., Studer A., Schapira A., Smith T. What shouldvaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS ONE 2008, 3(9):3193.